Product Information
LOTEMAX SM 0.38% OPHTH GEL is a brand product labeled by Bausch & Lomb Incorporated, priced at $49.4846 per GM under NDC 24208050707. Its NADAC has been published 377 times since Jul 17, 2019.
FDA first approved this application on Feb 22, 2019. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
The High Outlier badge above means this manufacturer's average price in the loteprednol etabonate market falls above Q3 + 1.5·IQR across all competing manufacturers. We only apply this flag in markets with four or more competitors. Full definition: glossary → outlier.
Strength
3.8 mg/g
Manufacturer
Bausch & Lomb IncorporatedNDC
24208050707
Classification
Brand
Dosage Form
GEL
Route
OPHTHALMIC
Effective Date
9/23/2026
Active Ingredients
LOTEPREDNOL ETABONATEApproval Type
New Drug (NDA)
FDA Application
NDA208219FDA Approved
2/22/2019
TE Code
AB
On Market Since
2/25/2019
Pharmacological Classes
Price Statistics
The NADAC for LOTEMAX SM 0.38% OPHTH GEL has been published 377 times since Jul 17, 2019, and over the history we have for it it has risen 35.2%. The table below summarizes its recorded NADAC range and movement.
| Current price | $49.4846 per GM |
|---|---|
| All-time high | $49.6720 (May 14, 2025) |
| All-time low | $36.5996 (Jul 17, 2019) |
| 52-week high | $49.5562 |
| 52-week low | $49.4681 |
| Median price | $46.0569 |
| Average price | $44.6397 |
| Largest weekly change | +6.0% (Jan 10, 2024) |
| Weeks tracked | 377 |
| Tracking since | Jul 17, 2019 |
Generic Alternatives
No other NADAC-published product shares this drug's active ingredient and strength in a comparable dosage form. Compare the broader picture on the loteprednol etabonate market page.
Lowest-Cost Alternatives
No alternatives available
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Bausch & Lomb Incorporated manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
loteprednol etabonate market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Corticosteroid class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of LOTEMAX SM 0.38% OPHTH GEL?
The current National Average Drug Acquisition Cost (NADAC) for LOTEMAX SM 0.38% OPHTH GEL, manufactured by Bausch & Lomb Incorporated, is $49.4846 per GM (NDC 24208050707), effective Sep 30, 2026.
How has the price of LOTEMAX SM 0.38% OPHTH GEL changed over time?
Over the history we have for it, the NADAC for LOTEMAX SM 0.38% OPHTH GEL has risen 35.2%. It has been tracked across 377 weekly CMS publications since Jul 17, 2019.
What are the highest and lowest recorded NADAC prices for LOTEMAX SM 0.38% OPHTH GEL?
Since Jul 17, 2019, the NADAC for LOTEMAX SM 0.38% OPHTH GEL has ranged from a low of $36.5996 (Jul 17, 2019) to a high of $49.6720 (May 14, 2025), with a median of $46.0569 per GM.
Are there cheaper alternatives to LOTEMAX SM 0.38% OPHTH GEL?
No other NADAC-published product currently shares the active ingredient and strength of LOTEMAX SM 0.38% OPHTH GEL in a comparable dosage form, so no direct lower-cost alternative is listed.
Who manufactures LOTEMAX SM 0.38% OPHTH GEL?
LOTEMAX SM 0.38% OPHTH GEL (NDC 24208050707) is labeled by Bausch & Lomb Incorporated, and CMS classifies it as a brand product.